Inside stent placement is suitable for preoperative biliary drainage in patients with perihilar cholangiocarcinoma

• Published in: BMC gastroenterology Vol. 24; no. 1; p. 174
• Main Authors: Yamada, Reiko, Kuriyama, Naohisa, Tanaka, Takamitsu, Nose, Kenji, Nakamura, Yoshifumi, Miwata, Tetsuro, Tsuboi, Junya, Mizuno, Shugo, Nakagawa, Hayato
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 20.05.2024; BioMed Central; BMC
• Subjects: Adult; Aged; Aged, 80 and over; Bile Duct Neoplasms - surgery; Bile ducts; Biopsy; Cancer therapies; Chemotherapy; Cholangiocarcinoma; Cholangitis; Cholestasis - etiology; Cholestasis - surgery; Cholestasis - therapy; Classification; Comparative analysis; Deoxycytidine - administration & dosage; Deoxycytidine - analogs & derivatives; Deoxycytidine - therapeutic use; Drainage - methods; Endoscopic biliary stenting; Endoscopy; Ethics; Female; Gemcitabine; Hospitals; Humans; Implants; Inside stent; Klatskin Tumor - surgery; Localized perihilar cholangiocarcinoma; Lymphatic system; Male; Metastasis; Middle Aged; Neoadjuvant Therapy; Patient outcomes; Patients; Polyethylene; Preoperative biliary drainage; Preoperative Care - methods; Recurrence; Retrospective Studies; Stent (Surgery); Stents; Surgery; Surgical drains; Surgical outcomes; Time to recurrent biliary obstruction; Transplants & implants; Treatment Outcome; Wound drainage; Japan; Endoscopic biliary stenting; Localized perihilar cholangiocarcinoma; Time to recurrent biliary obstruction; Inside stent; Preoperative biliary drainage
• ISSN: 1471-230X; 1471-230X
• DOI: 10.1186/s12876-024-03266-z

Endoscopic biliary stenting (EBS) is commonly used for preoperative drainage of localized perihilar cholangiocarcinoma (LPHC). This study retrospectively compared the utility of inside stent (IS) and conventional stent (CS) for preoperative EBS in patients with LPHC. EBS was performed in 56 patients with LPHC. EBS involved the placement of a CS (n = 32) or IS (n = 24). Treatment outcomes were compared between these two groups. Preoperative recurrent biliary obstruction (RBO) occurred in 23 patients (71.9%) in the CS group and 7 (29.2%) in the IS group, with a significant difference (p = 0.002). The time to RBO (TRBO) was significantly longer in IS than in CS (log-rank: p < 0.001). The number of stent replacements was significantly lower in IS than CS [0.38 (0-3) vs. 1.88 (0-8), respectively; p < 0.001]. Gemcitabine-based neoadjuvant chemotherapy (NAC) was administered to 26 patients (46.4%). Among patients who received NAC, TRBO was longer in IS than in CS group (log-rank: p < 0.001). The IS group had a significantly shorter preoperative and postoperative hospital stay than the CS group (20.0 vs. 37.0 days; p = 0.024, and 33.5 vs. 41.5 days; p = 0.016).　 Both the preoperative and the postoperative costs were significantly lower in the IS group than in the CS group (p = 0.049 and p = 0.0034, respectively). Compared with CS, IS for preoperative EBS in LPHC patients resulted in fewer complications and lower re-intervention rates. The fact that the IS group had shorter preoperative and postoperative hospital stays and lower costs both preoperatively and postoperatively compared to the CS group may suggest that the use of IS has the potential to benefit not only the patient but also the healthcare system.